Trial Profile
Phase 1/2 Study of AMG 531 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Patients With Aggressive Non-Hodgkin's Lymphoma Receiving R-HyperCVAD Alternating With R-Ara-C/MTX
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Sep 2021
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Methotrexate; Rituximab; Vincristine
- Indications Thrombocytopenia
- Focus Adverse reactions
- 18 Nov 2014 New trial record